InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,741.50
(
-0.09%
)
Post# of 53906
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dDT

Send PM Follow Ignore
Followers 470
Posts 76416
Boards Moderated 3
Alias Born 03/31/2008

dDT

Re: None

Thursday, 12/18/2014 7:24:49 AM

Thursday, December 18, 2014 7:24:49 AM

Post# of 53906
AstraZeneca cancer drug cleared in Europe

The European Commission approves AstraZeneca's (NYSE:AZN) Lynparza (olaparib) for the maintenance treatment of adult patients with platinum-resistant relapsed BRCA-mutated (germline and/or somatic) high grade serious epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells. It is the first PARP inhibitor approved for patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer. Appropriate patients will be identified through a validated diagnostic test.
The company is investigating the efficacy of olaparib in other cancer types.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up